BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 31549317)

  • 1. The Landmark Series: Non-melanoma Skin Cancers.
    Lee AY; Berman RS
    Ann Surg Oncol; 2020 Jan; 27(1):22-27. PubMed ID: 31549317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.
    Komatsubara KM; Jeter J; Carvajal RD; Margolin K; Schadendorf D; Hauschild A
    Am Soc Clin Oncol Educ Book; 2017; 37():641-650. PubMed ID: 28561682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapy of skin carcinoma.
    Kempf RA
    Cancer Treat Res; 1995; 78():137-62. PubMed ID: 8595141
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy for Non-melanoma Skin Cancer.
    Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
    Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Melanoma Skin Cancers: Biological and Clinical Features.
    Cives M; Mannavola F; Lospalluti L; Sergi MC; Cazzato G; Filoni E; Cavallo F; Giudice G; Stucci LS; Porta C; Tucci M
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
    Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
    J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.
    Villani A; Potestio L; Fabbrocini G; Scalvenzi M
    Adv Ther; 2022 Mar; 39(3):1164-1178. PubMed ID: 35089534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
    Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
    Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
    Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
    Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical management of cutaneous malignancies.
    Gibbs P; Gonzalez R; Lee LA; Walsh P
    Clin Dermatol; 2001; 19(3):298-304. PubMed ID: 11479042
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimal treatment of unresectable nonmelanoma skin cancers.
    Olencki T
    J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):789-92. PubMed ID: 24853218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
    Frampton JE; Basset-Séguin N
    Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage.
    Zhu GA; Sundram U; Chang AL
    JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vismodegib in the treatment of advanced BCC.
    O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
    Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic treatment options for advanced epithelial skin cancer.
    Soura E; Chasapi V; Stratigos AJ
    Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.